Natco Pharma files audited results for FY26
The company confirms previously disclosed annual figures of ₹4,375.9 crore in revenue and ₹1,418.5 crore in net profit.
— 2 earlier stories on Natco Pharma Ltd. →What's new
- Natco Pharma released its formal audited financial statements for Q4 and FY26.
- The figures match the previously announced revenue of ₹4,375.9 crore and net profit of ₹1,418.5 crore.
- The filing includes standard segment data and auditor reports.
Why this matters
This is a procedural filing that confirms numbers the market already digested. It provides regulatory transparency but contains no surprises for investors.
What we're watching
- Details from the upcoming earnings call.
- Management commentary on margin sustainability for FY27.
- Updates on product pipeline launches.
The full read
Natco Pharma has filed its formal audited financial results for the year ended March 31, 2026. The report confirms the company's previously disclosed performance, with consolidated revenue of ₹4,375.9 crore and a net profit of ₹1,418.5 crore.
No surprises here.
Because these figures were already public, the filing is a procedural confirmation rather than a source of new information. It includes the full suite of audited statements, segment data, and auditor reports required for regulatory compliance. The market has already priced in these results. Investors should look to the upcoming earnings call for any additional context on the company's outlook for the new fiscal year, as the next test is whether the current margin profile holds through FY27.
Questions answered
- Are these financial results new?
- No. The consolidated revenue of ₹4,375.9 crore and net profit of ₹1,418.5 crore were already disclosed in a prior announcement.
- What does this filing contain?
- It provides the formal audited financial statements, segment-wise data, and auditor reports for the fiscal year ended March 31, 2026.
- Is there any change to the previously reported earnings?
- The filing serves as a detailed confirmation of the figures already shared with the market.
Story so far
All notes on NATCOPHARM →- 29 May 2026 · 4:18 PM IST Natco Pharma files audited results for FY26
- 1d ago Natco's trough is here. The growth math starts next year.
- 1d ago Natco Pharma profit drops 25% as annual revenue slips